Search hospitals

>

Illinois

>

Chicago

Northwestern University

Claim this profile

Chicago, Illinois 60611

Global Leader in Cancer

Global Leader in Breast Cancer

Conducts research for HIV Infection

Conducts research for Lung Cancer

Conducts research for Human Immunodeficiency Virus Infection

1949 reported clinical trials

209 medical researchers

Photo of Northwestern University in ChicagoPhoto of Northwestern University in ChicagoPhoto of Northwestern University in Chicago

Summary

Northwestern University is a medical facility located in Chicago, Illinois. This center is recognized for care of Cancer, Breast Cancer, HIV Infection, Lung Cancer, Human Immunodeficiency Virus Infection and other specialties. Northwestern University is involved with conducting 1,949 clinical trials across 2,256 conditions. There are 209 research doctors associated with this hospital, such as Sunandana Chandra, Aparna Kalyan, Amy Paller, and Seth M. Pollack.

Area of expertise

1

Cancer

Global Leader

Northwestern University has run 174 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II
2

Breast Cancer

Global Leader

Northwestern University has run 137 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
ER positive
HER2 negative

Top PIs

Clinical Trials running at Northwestern University

Lung Cancer

Breast Cancer

Skin Cancer

Breast cancer

Pancreatic Cancer

Kidney Cancer

Chronic Lymphocytic Leukemia

Bladder Cancer

Cervical Cancer

Prostate Cancer

Image of trial facility.

Radiotherapy

for Lung Cancer

This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approach is better or worse than the usual approach for lung cancer. The usual approach is defined as the care most people get for non-small cell lung cancer.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Proton Craniospinal Radiation

for Cancer in the Brain and Spinal Cord

This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal fluid filled space that surrounds the brain and spinal cord (leptomeningeal metastasis). Patients with leptomeningeal metastasis (LM) may develop multiple areas of nervous system (neurologic) impairment that can be life-threatening. Radiation therapy (RT) effectively relieves local symptoms due to LM. RT uses high energy radiography (x-rays), particles, or radioactive seeds to kill cancer cells and shrink tumors. IFRT is commonly used to treat symptoms of LM. IFRT is radiation treatment that uses x-rays to treat specific areas of LM and to relieve and/or prevent symptoms. pCSI uses protons that can be directed with more accuracy than x-rays which allows treatment of the entire central nervous system space containing the cerebrospinal fluid (CSF), brain, and spinal cord. The pCSI treatment could delay the worsening of LM. Giving pCSI may be better than IFRT in treating LM in patients with breast or non-small cell lung cancer.

Recruiting

2 awards

Phase 3

3 criteria

Image of trial facility.

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.

Recruiting

2 awards

Phase 3

31 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Northwestern University?

Where is Northwestern University located?

Who should I call to ask about financial aid or insurance network?

What insurance does Northwestern University accept?

What awards or recognition has Northwestern University received?